Bronstein, Gewirtz & Grossman, LLC Encourages SelectQuote, Inc. (SLQT) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SelectQuote, Inc. (NYSE: SLQT) securities who bought shares prior to September 9, 2020, and still hold them. The investigation focuses on whether SelectQuote and its officers engaged in corporate wrongdoing. The law firm encourages affected investors to contact them to assist with the investigation, noting that their representation is on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SelectQuote, Inc. (SLQT) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by SelectQuote, Inc. (NYSE:SLQT) and its officers/directors. The firm is encouraging investors who purchased SelectQuote securities prior to September 9, 2020, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors in class actions on a contingency fee basis and aims to restore investor capital and ensure corporate accountability.
SelectQuote, Inc. (SLQT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into SelectQuote, Inc. (SLQT) following concerns of potential corporate wrongdoing by its officers and/or directors. The firm is encouraging shareholders who purchased SelectQuote securities before September 9, 2020, and still hold them, to contact them to learn more and assist in the investigation. The firm operates on a contingency fee basis, meaning investors will not incur costs unless a recovery is successful.
Analysts Offer Insights on Financial Companies: Toronto Dominion Bank (TD) and SelectQuote (SLQT)
Analysts have provided new ratings for Toronto Dominion Bank (TD) and SelectQuote (SLQT) within the Financial sector. Matthew Lee from Canaccord Genuity maintained a Buy rating on TD with a C$141.00 price target, while RBC Capital's Ben Hendrix maintained a Hold rating on SelectQuote with a $3.00 price target. The consensus for TD is a Moderate Buy with a slight downside, and for SLQT, it's a Moderate Buy with a significant upside.
SelectQuote, Inc. (SLQT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against SelectQuote, Inc. (NYSE:SLQT) on behalf of investors who purchased securities prior to September 9, 2020, and still hold them. The investigation focuses on whether SelectQuote's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected stockholders to contact them for more information, offering their services on a contingency fee basis.
SLQT: RBC Capital Lowers Price Target to $3.00 While Maintaining Rating | SLQT Stock News
RBC Capital has lowered its price target for SelectQuote (SLQT) from $5.00 to $3.00, while maintaining a 'Sector Perform' rating. This adjustment reflects a 40% decrease in the target price, following previous reductions in November and August 2025. Despite the lowered target, Wall Street analysts project an average target price of $3.56 for SLQT, implying a 315.79% upside from its current price, with an "Outperform" consensus recommendation.
SelectQuote (NYSE:SLQT) Given New $3.00 Price Target at Royal Bank Of Canada
Royal Bank of Canada has cut its price target for SelectQuote (NYSE:SLQT) from $5.00 to $3.00, while maintaining a "sector perform" rating, suggesting a significant upside from its current price. Despite recently beating EPS and revenue estimates, analysts project a negative full-year EPS, indicating cautious expectations for the company. The stock is currently trading near its 12-month low, with institutional investors showing mixed activity in their holdings.
SelectQuote, Inc. (NYSE:SLQT) Stock's 31% Dive Might Signal An Opportunity But It Requires Some Scrutiny
SelectQuote (NYSE:SLQT) stock has recently fallen by 31%, resulting in an 83% loss over the past year. Despite a low price-to-sales (P/S) ratio of 0.1x compared to the industry average of 1.1x, the article suggests scrutiny is needed. The company has shown strong revenue growth but its low P/S ratio indicates market skepticism about future performance.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SelectQuote, Inc. (SLQT) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by SelectQuote, Inc. (NYSE: SLQT) and certain of its officers and directors. The firm encourages investors who purchased SelectQuote securities prior to September 9, 2020, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis for class actions, seeking to restore investor capital and ensure corporate accountability.
SelectQuote, Inc. (SLQT) implements strategic and financial initiatives to support expansion
SelectQuote, Inc. has announced the implementation of new strategic and financial initiatives aimed at supporting its expansion efforts. These measures are designed to strengthen the company's position and facilitate its growth objectives. The announcement highlights SelectQuote's commitment to evolving its business model for future success.
SelectQuote, Inc. (SLQT) Implements Strategic and Financial Initiatives to Support Expansion
SelectQuote, Inc. (NYSE: SLQT) has announced strategic and financial initiatives to support its expansion, including a new multi-year agreement for its SelectRx pharmacy with a major pharmacy benefit manager, effective January 1, 2026. This agreement is expected to enhance reimbursement rate visibility and offer more predictable economics for Medicare. Additionally, SelectQuote secured a $415 million senior secured credit facility to refinance existing debt, support working capital, reduce capital costs, and improve liquidity.
SelectQuote (SLQT) Earnings Call: Growth Amid Headwinds
SelectQuote (SLQT) reported strong Q2 earnings, with double-digit revenue growth and near-record profitability in its senior segment, alongside rapid expansion of its SelectRx pharmacy business. Despite trimming fiscal 2026 guidance due to pharmacy benefit reimbursement adjustments and a major carrier's marketing pullback, management emphasized structural improvements in margins, cash flow, and balance sheet flexibility. The company expects significant improvement in operating cash flow for fiscal 2026, aiming for long-term growth by prioritizing efficiency and strategic initiatives.
Bronstein, Gewirtz & Grossman, LLC Encourages SelectQuote, Inc. (SLQT) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against SelectQuote, Inc. Investors who purchased SelectQuote securities before September 9, 2020, and still hold them, are urged to contact the firm to assist with the investigation into potential corporate wrongdoing by the company's officers and/or directors. The firm operates on a contingency fee basis, meaning investors incur no upfront cost.
SelectQuote (SLQT) Q2 Profit Beat And Low P/E Challenge Bearish Earnings Narratives
SelectQuote (SLQT) posted strong Q2 2026 results with a profit beat, reporting revenue of US$537.1 million and EPS of US$0.37. The company's recent profitability challenges earlier loss-making narratives, with a trailing 12-month net income of US$55.2 million and a low P/E of 3.5x compared to peers. However, analysts note concerns about substantial forecasted EPS declines and weak interest coverage, suggesting caution despite the recent return to profit.
SelectQuote (SLQT) Earnings Call: Growth Amid Headwinds
SelectQuote (SLQT) reported double-digit revenue growth and near-record profitability in its senior segment, alongside rapid expansion of its SelectRx pharmacy business, demonstrating strong operational execution. Despite this, the company trimmed its fiscal 2026 guidance due to a pharmacy benefit reimbursement adjustment and a major carrier's marketing pullback, resulting in a ~$40 million headwind. SelectQuote's management believes structural improvements in margins, cash flow, and the balance sheet will outweigh these temporary pressures, supporting a positive long-term outlook.
Selectquote Shares Show Strong Quarterly Performance Amid Strategic Shifts
Selectquote, Inc. reported strong financial results for its second fiscal quarter of 2026, exceeding market expectations with a 12% year-over-year revenue increase to $537 million and EPS of $0.26. The company secured a new $415 million credit facility and entered a multi-year PBM agreement for its SelectRx service to strengthen its balance sheet and improve operational predictability. Despite the positive earnings and strategic moves, the stock declined in pre-market trading, indicating investor caution regarding the volatile insurance sector.
Selectquote Shares Show Strong Quarterly Performance Amid Strategic Shifts
Selectquote, Inc. reported strong financial results for its second fiscal quarter of 2026, exceeding market expectations with a 12% year-over-year revenue increase to $537 million and earnings per share of $0.26. The growth was primarily driven by its Healthcare Services unit, which saw a 26% revenue surge. Despite this positive performance and strategic moves like securing a new $415 million credit facility and a multi-year PBM agreement, Selectquote's stock declined in pre-market trading, indicating cautious investor sentiment regarding the volatile insurance sector.
SelectQuote (NYSE:SLQT) Upgraded to Hold at Wall Street Zen
SelectQuote (NYSE:SLQT) was upgraded to a "hold" rating by Wall Street Zen, shifting from a previous "sell" rating. The company recently reported better-than-expected earnings with an EPS of $0.26 against an anticipated $0.17 and significant revenue. Despite a high PE ratio of 109.11, institutional investors have increased their stakes in the insurance brokerage firm.
SelectQuote lowers 2026 guidance amid $40M headwind but targets 20%+ senior EBITDA margin and $25–35M operating cash flow
SelectQuote has lowered its 2026 guidance due to a $40 million headwind, but the company is still aiming for a senior segment adjusted EBITDA margin of over 20% and an operating cash flow between $25 million and $35 million. This indicates a strategic adjustment in financial targets while maintaining a focus on profitability and cash generation in its core senior segment.
SelectQuote, Inc. (NYSE:SLQT) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
SelectQuote, Inc. (NYSE:SLQT) has seen its share price drop by 27% in the last month and 77% over the last year. Despite strong recent revenue growth of 13% (and 103% over three years) and a forecasted 10% growth for the next year (compared to an industry average of 2.3%), the company trades at a low price-to-sales (P/S) ratio of 0.1x, significantly below the industry average of 1.1x. This suggests that while there's an opportunity due to depressed valuation, shareholders may be skeptical of future forecasts or pricing in certain risks.
SelectQuote, Inc. (NYSE:SLQT) Q2 2026 Earnings Call Transcript
SelectQuote, Inc. (NYSE: SLQT) announced strong Q2 2026 earnings, reporting $0.3729 EPS against an expectation of $0.17. Despite a strong quarter, the company lowered its fiscal 2026 guidance by $40 million due to a national carrier partner cutting their marketing budget and a PBM reimbursement headwind. SelectQuote emphasized its operational execution, strong senior EBITDA margins, rapid growth in its healthcare services segment with SelectRx, and improved capital flexibility through a new $415 million credit facility.
SelectQuote lowers 2026 guidance amid $40M headwind but targets 20%+ senior EBITDA margin and $25–35M operating cash flow
SelectQuote (NYSE: SLQT) has lowered its 2026 financial guidance due to a $40 million headwind, but it still expects to achieve a senior EBITDA margin of over 20%. The company is also targeting an operating cash flow of $25–35 million for the same period. This indicates a strategic adjustment in its financial outlook while maintaining profitability goals.
SelectQuote: Fiscal Q2 Earnings Snapshot
SelectQuote, Inc. (SLQT) reported strong fiscal second-quarter earnings, with net income of $69.3 million, or 26 cents per share, on revenue of $537.1 million. The company expects full-year revenue to be between $1.61 billion and $1.71 billion. This positive outlook follows a successful quarter for the Overland Park, Kansas-based company.
SelectQuote, Inc. (NYSE:SLQT) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
SelectQuote, Inc. (NYSE:SLQT) has experienced a significant 27% drop in its stock price over the last 30 days, contributing to a 77% loss for shareholders over the past year. Despite this, its low P/S ratio of 0.1x, compared to an industry average above 1.1x, could indicate an undervalued opportunity. The company has shown strong revenue growth of 13% in the last year and 103% over three years, with analysts forecasting 10% growth for the next year against an industry average of 2.3%.
After Plunging 27.0% in 4 Weeks, Here's Why the Trend Might Reverse for SelectQuote (SLQT)
SelectQuote (SLQT) has recently experienced a 27% decline in its stock price over the past four weeks, placing it in oversold territory according to its Relative Strength Index (RSI) of 27.27. Despite the recent drop, analysts are raising earnings estimates for the current year, with a 9.1% increase in the consensus EPS estimate over the last 30 days. Coupled with a Zacks Rank #2 (Buy), these factors suggest a potential near-term turnaround for the stock.
SelectQuote Q2 2026 Earnings: $69.3M Net Income, $537.1M Revenue - News and Statistics
SelectQuote, Inc. (SLQT) reported a net income of $69.3 million for its fiscal second quarter of 2026, translating to 26 cents per share. The company posted revenues of $537.1 million for the period and anticipates full-year revenue to be between $1.61 billion and $1.71 billion. This financial update provides key performance indicators for the Overland Park, Kansas-based company.
SelectQuote: Fiscal Q2 Earnings Snapshot
SelectQuote, Inc. (SLQT) announced its fiscal second-quarter earnings, reporting $69.3 million in net income, or 26 cents per share. The company generated revenue of $537.1 million for the period and projects its full-year revenue to be between $1.61 billion and $1.71 billion. This financial update was generated using data from Zacks Investment Research.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against SelectQuote, Inc. (SLQT) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against SelectQuote, Inc. (NYSE: SLQT) concerning alleged corporate wrongdoing by the company's officers and/or directors. The firm is encouraging investors who purchased SelectQuote securities before September 9, 2020, and still hold them, to come forward to assist with the investigation. The investigation aims to restore investor capital and ensure corporate accountability.
SelectQuote Holds 2025 Annual Stockholders Meeting
SelectQuote announced it held its 2025 Annual Stockholders Meeting. The article, originating from MSN, states the core information is the occurrence of this meeting. No further details about the outcomes or specific agenda of the meeting are provided.
SelectQuote (SLQT) Projected to Post Quarterly Earnings on Thursday
SelectQuote (SLQT) is projected to announce its Q2 2026 earnings before market open on Thursday, February 5th. Analysts anticipate earnings of $0.17 per share and revenue of $530.7260 million for the quarter. The company's stock currently trades at $1.49, with institutional investors holding 34.59% of shares, and analysts currently have a consensus "Hold" rating with a target price of $3.88.
Bronstein, Gewirtz & Grossman, LLC Is Investigating SelectQuote, Inc. (SLQT) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against SelectQuote, Inc. (NYSE: SLQT) for alleged corporate wrongdoing. The firm encourages shareholders who purchased SelectQuote securities before September 9, 2020, and continue to hold them, to contact them to assist with the investigation. The investigation aims to restore investor capital and ensure corporate accountability.
SelectQuote to Release Fiscal Second Quarter 2026 Earnings on February 5
SelectQuote, Inc. (NYSE: SLQT) announced it will release its fiscal second-quarter 2026 financial results before market open on Thursday, February 5, 2026. CEO Tim Danker and CFO Ryan Clement will host a conference call on the same day at 8:00 am ET to discuss the results. Interested parties can access the live webcast or register for dial-in details via the company's investor relations website.
SelectQuote, Inc. (NYSE:SLQT) Receives Consensus Recommendation of "Hold" from Brokerages
SelectQuote, Inc. (NYSE:SLQT) has received a consensus "Hold" recommendation from brokerages, with an average one-year price target of $3.875. The company's shares opened at $1.64, and institutional investors hold about 34.59% of the stock, with several funds recently increasing their stakes. SelectQuote reported quarterly EPS of ($0.26), beating estimates, and is an insurance brokerage specializing in connecting consumers with various insurance products.
SelectQuote to Release Fiscal Second Quarter 2026 Earnings on February 5
SelectQuote, Inc. (NYSE: SLQT) announced it will release its fiscal second quarter 2026 financial results before market open on Thursday, February 5, 2026. CEO Tim Danker and CFO Ryan Clement will host a conference call on the same day at 8:00 am ET to discuss the results, with interested parties encouraged to access a live webcast or register for the call.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SelectQuote, Inc. (SLQT) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by SelectQuote, Inc. (NYSE: SLQT) and certain of its officers and/or directors. The firm is encouraging investors who purchased SelectQuote securities before September 9, 2020, and continue to hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC specializes in securities fraud class actions and shareholder derivative suits, operating on a contingency fee basis.
University of Kansas Study Shows e-Brokers Like SelectQuote Extend Rural Residents’ Access to Medicare Advantage Plans
A University of Kansas study, in collaboration with SelectQuote, found that e-brokers significantly improve access to Medicare Advantage plans for rural residents, especially in areas lacking local licensed agents. The research across 10 rural states revealed approximately 400,000 residents live in counties without a local Medicare insurance broker, creating substantial access hurdles. SelectQuote's technology-enabled platform helps close these gaps, serving low-income individuals and those in remote locations, and generally offering a broader range of plans in lower-income counties.
SelectQuote, Inc. (SLQT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by SelectQuote, Inc. (SLQT) and its officers/directors. The law firm is encouraging shareholders who purchased SelectQuote securities before September 9, 2020, and continue to hold them, to contact the firm to learn more and assist with the investigation. The firm operates on a contingency fee basis, meaning investors incur no upfront costs.
Press Release: Pathlight Capital Serves as Administrative Agent on $415,000,000 Senior Secured Credit Facility for SelectQuote, Inc.
Pathlight Capital has acted as the administrative agent for a $415,000,000 senior secured credit facility for SelectQuote, Inc. This press release announces the financial arrangement. The article also briefly mentions Unity Software's fourth-quarter financial results, including a 35% year-over-year revenue increase to $609 million and a loss of 66 cents per share.
Has SelectQuote, Inc.'s (NYSE:SLQT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
SelectQuote Inc.'s stock has seen a significant 19% rise over the past month. This article examines whether the company's financial fundamentals, specifically its Return on Equity (ROE), justify this stock performance. Despite an acceptable 11% ROE, the company's net income has declined by 5.5% over five years, contrasting with the industry's 11% growth, leading to questions about its capital allocation and future growth prospects.
SelectQuote Announces New Multiyear Agreement with SelectRx PBM Partner
SelectQuote announced a new multiyear agreement between its SelectRx pharmacy and a key PBM partner, effective January 1, 2026. This agreement is expected to provide enhanced reimbursement rate predictability and financial stability for SelectRx, allowing continued investment and growth. CEO Tim Danker highlighted that the contract recognizes the clinical value SelectRx provides to its over 100,000 Medicare beneficiaries with chronic conditions.
Has SelectQuote, Inc.'s (NYSE:SLQT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
SelectQuote (NYSE:SLQT) has seen a 19% stock increase in the past month. Despite an acceptable 11% Return on Equity (ROE), the company's net income has declined by 5.5% over five years, contrasting with industry growth. This suggests that while ROE is decent and profits are fully reinvested, external factors or poor capital allocation might be hindering earnings growth, which analysts expect to continue shrinking.
Has SelectQuote, Inc.'s (NYSE:SLQT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
SelectQuote (NYSE:SLQT) has seen a significant 19% stock price increase recently. However, its 11% Return on Equity (ROE) has not translated into earnings growth, with net income declining by 5.5% over the past five years, contrasting with an industry average growth of 11%. Despite reinvesting all profits, the company's earnings are still expected to shrink in the future due to external factors, raising questions about the sustainability of its stock performance.
SelectRx PBM deal steadiess reimbursement for 100,000 patients nationwide
SelectQuote (NYSE: SLQT) announced that its SelectRx pharmacy has secured a new multiyear agreement with a key pharmacy benefit manager (PBM) partner, effective January 1, 2026. This deal is expected to provide enhanced reimbursement rate predictability and financial stability for SelectRx, which serves over 100,000 Medicare beneficiaries with chronic conditions across the U.S. The agreement, combined with a recent capital structure refinancing, allows SelectQuote to focus on business operations and driving shareholder value.
SelectQuote secures multiyear agreement with major PBM partner By Investing.com
SelectQuote, Inc. announced that its SelectRx pharmacy has secured a new multiyear agreement with a major pharmacy benefit manager, effective January 1, 2026, which is expected to provide greater visibility into reimbursement rates and align with financial expectations. Despite a significant stock price drop over the past year, the company, valued at a $271 million market capitalization, shows solid financials and appears undervalued according to InvestingPro analysis. This agreement follows recent capital refinancing and is set to support the growth of its SelectRx pharmacy, serving over 100,000 Medicare beneficiaries.
SelectQuote Announces New Multiyear Agreement with SelectRx PBM Partner
SelectQuote (NYSE: SLQT) announced that its SelectRx pharmacy has secured a new multiyear agreement with a major Pharmacy Benefit Manager (PBM) partner, effective January 1, 2026. This agreement aims to provide enhanced reimbursement rate predictability and stability, aligning with expectations set in SelectQuote's Q1 fiscal 2026 earnings call. CEO Tim Danker emphasized that the new contract, alongside recent capital structure refinancing, will enable greater focus on business operations and driving cash flow for shareholders.
SelectQuote secures multiyear agreement with major PBM partner
SelectQuote (NYSE:SLQT) announced a new multiyear agreement for its SelectRx pharmacy with a major pharmacy benefit manager (PBM) partner, effective January 1, 2026. This agreement is expected to provide greater visibility into reimbursement rates, offering more predictable financial outcomes for the company's Medicare insurance distribution pharmacy business. Despite a recent stock price decline, InvestingPro analysis suggests SelectQuote, with revenues of $1.56 billion, is undervalued.
SelectQuote Announces New Multiyear Agreement with SelectRx PBM Partner
SelectQuote, Inc. announced a new multiyear agreement between its SelectRx pharmacy and a significant PBM partner, effective January 1, 2026. This agreement is expected to enhance financial consistency, provide predictable reimbursement rates, and allow continued investment in the SelectRx pharmacy, which serves over 100,000 Medicare beneficiaries with chronic conditions. CEO Tim Danker stated that the contract, along with recent refinancing, will enable accelerated growth and meaningful cash flow for shareholders by focusing on operational execution.
Pathlight Capital provides $415 million credit facility to SelectQuote By Investing.com
Pathlight Capital has provided SelectQuote, Inc. with a senior secured credit facility of $415 million, with $325 million being a term loan. This funding aims to refinance existing debt, enhance liquidity, and support growth in SelectQuote's health insurance and healthcare service businesses. Despite recent stock surges and a low P/E ratio, analysts forecast a decrease in net income for SelectQuote this year.
Pathlight Capital provides $415 million credit facility to SelectQuote By Investing.com
Pathlight Capital has provided SelectQuote with a $415 million senior secured credit facility, including a $325 million term loan, to refinance existing debt and bolster working capital. This financing aims to lower SelectQuote's cost of capital and improve liquidity, supporting its growth in senior health insurance and healthcare services. Despite a mixed outlook from analysts regarding net income, the company's CEO believes the funding provides essential flexibility.
Pathlight Capital provides $415 million credit facility to SelectQuote By Investing.com
Pathlight Capital LP has provided a $415 million senior secured credit facility to SelectQuote, Inc., a Medicare insurance distributor. This financing includes a $325 million term loan from Pathlight, intended to refinance existing debt and bolster working capital. The move aims to cut SelectQuote's cost of capital and increase liquidity, despite analysts forecasting a drop in net income this year.
